← Back to Search

Other

MBL949 Arm 4 for Obesity

Phase 2
Waitlist Available
Research Sponsored by Novartis Pharmaceuticals
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline to day 169

Summary

This trial is testing a new treatment called MBL949 to help people who are overweight or have Type 2 Diabetes. The study includes a period to check participants' health, followed by several weeks of treatment and a follow-up. MBL949 aims to help manage weight and blood sugar levels better than current treatments.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline to day 169
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to day 169 for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change-from-baseline in Weight
Frequency and Severity of Adverse Events

Trial Design

6Treatment groups
Active Control
Placebo Group
Group I: MBL949 Arm 4Active Control1 Intervention
MBL949 one 1.5 mg dose followed by seven doses of 2.2 mg
Group II: MBL949 Arm 1Active Control1 Intervention
MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 4.5 mg
Group III: MBL949 Arm 5Active Control1 Intervention
MBL949 one 3 mg dose followed by two doses of 6 mg followed by five doses of 7.5 mg
Group IV: MBL949 Arm 2Active Control1 Intervention
MBL949 two 3 mg doses followed by six doses of 4.5 mg
Group V: MBL949 Arm 3Active Control1 Intervention
MBL949 one 12 mg dose followed by seven doses of 4.5 mg
Group VI: PlaceboPlacebo Group1 Intervention
Placebo to MBL949

Find a Location

Who is running the clinical trial?

Novartis PharmaceuticalsLead Sponsor
2,911 Previous Clinical Trials
4,250,551 Total Patients Enrolled
6 Trials studying Obesity
793 Patients Enrolled for Obesity
~34 spots leftby Nov 2025